Nice_老虎社区_美港股上老虎

2022-01-15

Nice

3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":697972401,"tweetId":"697972401","gmtCreate":1642247496132,"gmtModify":1642247496497,"author":{"id":3574766349354741,"idStr":"3574766349354741","authorId":3574766349354741,"authorIdStr":"3574766349354741","name":"TK360","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":36,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Nice&nbsp;</body></html>","htmlText":"<html><head></head><body>Nice&nbsp;</body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/697972401","repostId":1134509683,"repostType":4,"repost":{"id":"1134509683","kind":"news","pubTimestamp":1641612579,"share":"https://www.laohu8.com/m/news/1134509683?lang=zh_CN&edition=full","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<html><head></head><body>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.<blockquote><html><head></head><body>这是新的一年，新冠肺炎仍然和我们在一起。去年，我们看到医疗保健领域多种新冠疫苗和治疗方法获得了紧急使用授权。制药公司将在2022年赚取数十亿美元。以下是三只应该蓬勃发展的股票。</body></html></blockquote>Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.<blockquote>辉瑞（纽约证券交易所股票代码：PFE）是一家价值3100亿美元的大型公司，预计其新冠疫苗和抗病毒药物的销售额将不会是10亿或100亿美元，而是超过500亿美元。斗志昂扬Novavax（纳斯达克：NVAX）终于在全球范围内推出了新冠疫苗。它将获得多少亿？我们有一个黑马候选人维尔生物技术（纳斯达克：维尔）。对于这家小型生物技术公司来说，它的一种药物很容易成为价值10亿美元的重磅炸弹。</blockquote><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>A safe harbor in stormy weather<blockquote>暴风雨天气中的避风港</blockquote>George Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.<blockquote>乔治·巴德威尔（辉瑞）：辉瑞是新冠肺炎制药产品无可争议的冠军。仅在2022年，华尔街预计这家制药巨头的新型冠状病毒疫苗Comirnaty和口服抗病毒药物Paxlovid的销售额就将达到550亿美元。</blockquote>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.<blockquote>更重要的是，分析师开始接受Paxlovid可能在当前十年内成为该公司可持续收入来源的想法。当该药物上个月首次被美国食品和药物管理局根据紧急使用授权途径允许上市时，华尔街认为从商业角度来看，Paxlovid可能会在一年左右的时间内达到顶峰，然后随着疫情从视野中消失，销售额急剧下降。</blockquote>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.<blockquote>但距离该药物首次获得批准还不到三周，令人痛苦的是，很明显，Paxlovid可能需要作为未来几年COVID-19最坏结果的故障保险。毕竟，高传染性的奥密克戎变种肯定不会是该病毒的最后一次重大迭代。</blockquote>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.<blockquote>这一切意味着，辉瑞应该是少数几家在新冠肺炎拥有可观、长期收入来源的大型制药商之一。反过来，在可预见的未来，辉瑞应该有充足的自由现金流来满足其慷慨的股东奖励计划以及雄心勃勃的业务发展计划。</blockquote>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.<blockquote>因此，如果您正在寻找一只能够抵御极高通胀和利率上升双重阻力的股票，辉瑞可能值得一试。</blockquote>Revenue forecasts for Novavax:  $2 billion to $8 billion<blockquote>Novavax的收入预测：20亿至80亿美元</blockquote>Taylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.<blockquote>泰勒·卡迈克尔（Novavax）：Novavax今年正处于伟大的边缘。该公司的股价跌至每股125美元。这就是它在2021年开始的地方，所以去年该股几乎遭受了洗盘。</blockquote>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.<blockquote>早在2月份，当Novavax报告其新冠疫苗的积极3期数据时，股价就飙升至300美元以上。但后来这家小型生物技术公司遇到了制造问题。虽然许多人说它的疫苗是同类产品中最好的，但扩大约20亿剂疫苗的合同生产说起来容易做起来难。这些现实导致该股较高点下跌约60%。</blockquote>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.<blockquote>尽管如此，Novavax的收入已经达到了10亿美元大关，因此由于所有的预订，其疫苗甚至在获得批准之前就已经一鸣惊人。现在，全球各地的授权纷至沓来，Novavax很有可能在2022年运送大量疫苗。该公司已经实现了每月1亿剂的生产能力，即一年12亿剂。在第三季度收益看涨期权上，管理层预测到第四季度末将达到每月1.5亿剂（或每年18亿剂）的生产能力。该公司预计将继续扩大规模，并预测2022年将分发20亿剂疫苗。</blockquote>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.<blockquote>20亿剂疫苗，价格为16美元（曲速行动支付了16亿美元预购了1亿剂疫苗），我们粗略计算出收入为320亿美元。当然，Novavax将以较低的速度向发展中国家分发大量疫苗。尽管该公司对其价格保持沉默，但丹麦早在8月份就表示，根据欧盟(EU)协议，它为每剂疫苗支付了近21美元。欧盟已经订购了2亿剂，因此仅在欧洲的销售额就超过40亿美元。</blockquote>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.<blockquote>分析师非常保守，对Novavax 2022年的预测在20亿至80亿美元之间。（该公司的市值为90亿美元。）虽然一路上可能会出现一些问题，但Novavax肯定会在2022年从其COVID-19疫苗中赚取数十亿美元。如果该公司确实像其所说的那样交付20亿剂疫苗，该股可能会有大幅上涨空间。</blockquote>The antibody market all to itself<blockquote>抗体市场全靠自己</blockquote>Patrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.<blockquote>Patrick Bafuma（Vir Biotechnology）：奥密克戎变种目前猖獗，这一次，我们缺少一些治疗方法。以前青睐的单克隆抗体治疗来自礼来公司（bamlanivimab加etesevimab）以及来自罗氏和再生被认为对当前变体的活性显著降低。这样就只剩下一种对奥密克戎有效的输液了--葛兰素史克以及Vir Biotechnology的sotrovimab。这种单克隆抗体先前证明，在轻度至中度新冠肺炎和进展为重度疾病的高风险成人中，住院和死亡风险降低了79%。它是目前唯一一个对抗奥密克戎变种的人。</blockquote>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.<blockquote>作为唯一的单克隆抗体将有其特权。2021年前9个月，REGEN-COV带来了35亿美元的产品净销售额，而礼来公司的抗体组合带来了11.7亿美元。美国政府已经签订了价值约10亿美元的sotrovimab合同。随着医院挤满了病人，任何有助于缓解系统压力的东西都可能受到高度追捧。</blockquote>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.<blockquote>虽然辉瑞的Paxlovid将极大地有利于减轻医疗保健系统的COVID-19负担，但这种口服药物具有显着且复杂的药物相互作用潜力。事实上，它的相互作用列表读起来就像是常用处方药的名人录。这包括流行的血液稀释剂，如波立维和Xarelto，常见的止痛药，如曲马多和羟考酮，抗焦虑药，如Klonopin和Xanax，以及抗胆固醇他汀类药物。随着美国国立卫生研究院发表声明，表达了对Paxlovid可能的药物相互作用的担忧，这为sotrovimab继续广泛使用留下了充足的空间。根据与GSK的协议，Vir获得了sotrovimab销售额的72.5%，这家价值44亿美元的生物技术公司目前看起来很划算。</blockquote></body></html><blockquote></blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2022-01-08 11:29\n\n</h4>\n</header>\n<article>\n<html><head></head><body>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.<blockquote><html><head></head><body>这是新的一年，新冠肺炎仍然和我们在一起。去年，我们看到医疗保健领域多种新冠疫苗和治疗方法获得了紧急使用授权。制药公司将在2022年赚取数十亿美元。以下是三只应该蓬勃发展的股票。</body></html></blockquote>Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.<blockquote>辉瑞（纽约证券交易所股票代码：PFE）是一家价值3100亿美元的大型公司，预计其新冠疫苗和抗病毒药物的销售额将不会是10亿或100亿美元，而是超过500亿美元。斗志昂扬Novavax（纳斯达克：NVAX）终于在全球范围内推出了新冠疫苗。它将获得多少亿？我们有一个黑马候选人维尔生物技术（纳斯达克：维尔）。对于这家小型生物技术公司来说，它的一种药物很容易成为价值10亿美元的重磅炸弹。</blockquote><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>A safe harbor in stormy weather<blockquote>暴风雨天气中的避风港</blockquote>George Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.<blockquote>乔治·巴德威尔（辉瑞）：辉瑞是新冠肺炎制药产品无可争议的冠军。仅在2022年，华尔街预计这家制药巨头的新型冠状病毒疫苗Comirnaty和口服抗病毒药物Paxlovid的销售额就将达到550亿美元。</blockquote>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.<blockquote>更重要的是，分析师开始接受Paxlovid可能在当前十年内成为该公司可持续收入来源的想法。当该药物上个月首次被美国食品和药物管理局根据紧急使用授权途径允许上市时，华尔街认为从商业角度来看，Paxlovid可能会在一年左右的时间内达到顶峰，然后随着疫情从视野中消失，销售额急剧下降。</blockquote>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.<blockquote>但距离该药物首次获得批准还不到三周，令人痛苦的是，很明显，Paxlovid可能需要作为未来几年COVID-19最坏结果的故障保险。毕竟，高传染性的奥密克戎变种肯定不会是该病毒的最后一次重大迭代。</blockquote>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.<blockquote>这一切意味着，辉瑞应该是少数几家在新冠肺炎拥有可观、长期收入来源的大型制药商之一。反过来，在可预见的未来，辉瑞应该有充足的自由现金流来满足其慷慨的股东奖励计划以及雄心勃勃的业务发展计划。</blockquote>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.<blockquote>因此，如果您正在寻找一只能够抵御极高通胀和利率上升双重阻力的股票，辉瑞可能值得一试。</blockquote>Revenue forecasts for Novavax:  $2 billion to $8 billion<blockquote>Novavax的收入预测：20亿至80亿美元</blockquote>Taylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.<blockquote>泰勒·卡迈克尔（Novavax）：Novavax今年正处于伟大的边缘。该公司的股价跌至每股125美元。这就是它在2021年开始的地方，所以去年该股几乎遭受了洗盘。</blockquote>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.<blockquote>早在2月份，当Novavax报告其新冠疫苗的积极3期数据时，股价就飙升至300美元以上。但后来这家小型生物技术公司遇到了制造问题。虽然许多人说它的疫苗是同类产品中最好的，但扩大约20亿剂疫苗的合同生产说起来容易做起来难。这些现实导致该股较高点下跌约60%。</blockquote>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.<blockquote>尽管如此，Novavax的收入已经达到了10亿美元大关，因此由于所有的预订，其疫苗甚至在获得批准之前就已经一鸣惊人。现在，全球各地的授权纷至沓来，Novavax很有可能在2022年运送大量疫苗。该公司已经实现了每月1亿剂的生产能力，即一年12亿剂。在第三季度收益看涨期权上，管理层预测到第四季度末将达到每月1.5亿剂（或每年18亿剂）的生产能力。该公司预计将继续扩大规模，并预测2022年将分发20亿剂疫苗。</blockquote>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.<blockquote>20亿剂疫苗，价格为16美元（曲速行动支付了16亿美元预购了1亿剂疫苗），我们粗略计算出收入为320亿美元。当然，Novavax将以较低的速度向发展中国家分发大量疫苗。尽管该公司对其价格保持沉默，但丹麦早在8月份就表示，根据欧盟(EU)协议，它为每剂疫苗支付了近21美元。欧盟已经订购了2亿剂，因此仅在欧洲的销售额就超过40亿美元。</blockquote>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.<blockquote>分析师非常保守，对Novavax 2022年的预测在20亿至80亿美元之间。（该公司的市值为90亿美元。）虽然一路上可能会出现一些问题，但Novavax肯定会在2022年从其COVID-19疫苗中赚取数十亿美元。如果该公司确实像其所说的那样交付20亿剂疫苗，该股可能会有大幅上涨空间。</blockquote>The antibody market all to itself<blockquote>抗体市场全靠自己</blockquote>Patrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.<blockquote>Patrick Bafuma（Vir Biotechnology）：奥密克戎变种目前猖獗，这一次，我们缺少一些治疗方法。以前青睐的单克隆抗体治疗来自礼来公司（bamlanivimab加etesevimab）以及来自罗氏和再生被认为对当前变体的活性显著降低。这样就只剩下一种对奥密克戎有效的输液了--葛兰素史克以及Vir Biotechnology的sotrovimab。这种单克隆抗体先前证明，在轻度至中度新冠肺炎和进展为重度疾病的高风险成人中，住院和死亡风险降低了79%。它是目前唯一一个对抗奥密克戎变种的人。</blockquote>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.<blockquote>作为唯一的单克隆抗体将有其特权。2021年前9个月，REGEN-COV带来了35亿美元的产品净销售额，而礼来公司的抗体组合带来了11.7亿美元。美国政府已经签订了价值约10亿美元的sotrovimab合同。随着医院挤满了病人，任何有助于缓解系统压力的东西都可能受到高度追捧。</blockquote>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.<blockquote>虽然辉瑞的Paxlovid将极大地有利于减轻医疗保健系统的COVID-19负担，但这种口服药物具有显着且复杂的药物相互作用潜力。事实上，它的相互作用列表读起来就像是常用处方药的名人录。这包括流行的血液稀释剂，如波立维和Xarelto，常见的止痛药，如曲马多和羟考酮，抗焦虑药，如Klonopin和Xanax，以及抗胆固醇他汀类药物。随着美国国立卫生研究院发表声明，表达了对Paxlovid可能的药物相互作用的担忧，这为sotrovimab继续广泛使用留下了充足的空间。根据与GSK的协议，Vir获得了sotrovimab销售额的72.5%，这家价值44亿美元的生物技术公司目前看起来很划算。</blockquote></body></html><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","VIR":"Vir Biotechnology, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax:  $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"VIR":0.9}},"isVote":1,"tweetType":1,"viewCount":2743,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/697972401"}